Business Context and Reporting Period
This Form 8-K, dated May 15, 2017, reports the completion of a business combination between the registrant (formerly PharmAthene, Inc.) and Private Altimmune, Inc. The merger was finalized on May 4, 2017, pursuant to an Agreement and Plan of Merger and Reorganization dated January 18, 2017. The filing serves to provide audited financial statements for Private Altimmune for fiscal years ending December 31, 2015 and 2016, as well as unaudited pro forma combined financial data for the fiscal year ending December 31, 2016.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached exhibits (Exhibit 99.1 for audited statements and Exhibit 99.2 for pro forma data) which are incorporated by reference to a prior Form S-4/A filing.
Material Changes
The primary material change is the corporate restructuring resulting from the merger. The registrant has changed its name from PharmAthene, Inc. to Altimmune, Inc. following the combination with Private Altimmune. No specific operational or financial variance metrics are detailed in the text of this report.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from expectations due to various risks and uncertainties. The company disclaims any obligation to update these statements. Specific risks are referenced as being detailed in the "Risk Factors" section of the company's Form 10-K and other SEC reports. No specific guidance or management commentary on future performance is included in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in Exhibit 99.1 (Audited Financial Statements of Private Altimmune).
- Review the unaudited pro forma condensed combined financial data in Exhibit 99.2 to understand the combined entity's financial position as of December 31, 2016.
- Confirm the details of the Merger Agreement and any amendments referenced in the filing.
- Examine the "Risk Factors" section of the most recent Form 10-K for updated disclosures regarding the merged entity.